학술논문

Altered proliferation and networks in neural cells derived from idiopathic autistic individuals
Document Type
article
Source
Molecular Psychiatry. 22(6)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Stem Cell Research - Nonembryonic - Human
Stem Cell Research - Induced Pluripotent Stem Cell - Human
Clinical Research
Autism
Brain Disorders
Stem Cell Research
Neurosciences
Stem Cell Research - Nonembryonic - Non-Human
Regenerative Medicine
Intellectual and Developmental Disabilities (IDD)
Mental Health
Genetics
Stem Cell Research - Induced Pluripotent Stem Cell
Pediatric
2.1 Biological and endogenous factors
Aetiology
Neurological
Mental health
Adolescent
Autism Spectrum Disorder
Autistic Disorder
Brain
Cell Proliferation
Cells
Cultured
Child
Child
Preschool
Female
Fibroblasts
Humans
Induced Pluripotent Stem Cells
Insulin-Like Growth Factor I
Male
Neural Stem Cells
Neurogenesis
Neurons
Tissue Culture Techniques
beta Catenin
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Psychiatry
Clinical sciences
Biological psychology
Clinical and health psychology
Language
Abstract
Autism spectrum disorders (ASD) are common, complex and heterogeneous neurodevelopmental disorders. Cellular and molecular mechanisms responsible for ASD pathogenesis have been proposed based on genetic studies, brain pathology and imaging, but a major impediment to testing ASD hypotheses is the lack of human cell models. Here, we reprogrammed fibroblasts to generate induced pluripotent stem cells, neural progenitor cells (NPCs) and neurons from ASD individuals with early brain overgrowth and non-ASD controls with normal brain size. ASD-derived NPCs display increased cell proliferation because of dysregulation of a β-catenin/BRN2 transcriptional cascade. ASD-derived neurons display abnormal neurogenesis and reduced synaptogenesis leading to functional defects in neuronal networks. Interestingly, defects in neuronal networks could be rescued by insulin growth factor 1 (IGF-1), a drug that is currently in clinical trials for ASD. This work demonstrates that selection of ASD subjects based on endophenotypes unraveled biologically relevant pathway disruption and revealed a potential cellular mechanism for the therapeutic effect of IGF-1.